Using Megestrol Acetate During Covid-19

Short-term use of megestrol acetate for estrus prevention in cats during the Covid-19-related cessation of surgical sterilization in the U.S.

Last updated May 11, 2020   

Download PDF version (English)    |    En Español    |    Located outside of the U.S.? Click here


In light of the need to provide healthcare workers with protective gear, conserve resources, and to maintain social distancing, the U.S. Surgeon General issued an order to limit both human and veterinary “non-essential” or “elective” surgeries during the Covid-19 pandemic. Surgical sterilization (spay/neuter surgeries) are being defined by some organizations/local or state governments as non-essential. Animal welfare organizations and veterinarians are concerned about how this policy will impact their work. Several influential entities in veterinary medicine1,2,3 have advised animal shelters, spay/neuter clinics, and veterinarians to comply with this order by deferring sterilization surgeries for dogs and cats, and continuing to manage adoptions. Organizations and professionals are understandably worried that pregnancies will result in unwanted litters that will further stress shelter intake and the community when shelter resources will be low and community need high, especially during high seasonal reproduction for cats.

"COVID-19 brought a sudden need to evacuate animal shelters across the country, and communities responded by taking thousands of pets into their homes. There wasn’t even time to spay and neuter before they were placed. I support ACC&D’s recommendation that the field deploy megestrol acetate as a stop-gap contraceptive for female cats to prevent heat cycling and pregnancy until surgery comes back online."

- Dr. Julie Levy, DVM, PhD, DACVIM, DABVP

Alternatives to surgery

Any non-surgical contraceptive will need to be administered in accordance with human social distancing requirements to reduce the spread of Covid-19 and without the use personal protective equipment (PPE), such as gloves, masks, or gowns, to conserve those resources for human health. There are no drugs/vaccines that are approved in the U.S. for the suppression of fertility in either male or female cats. However, the progestin, megestrol acetate (MA) can be obtained (as described below) and may be used as an oral contraceptive when administered for a short duration to prevent estrus in queens while surgeries are delayed.

Target animals

This recommendation is for cats that can be individually treated at prescribed times with an accurate dose, and whose health can be monitored over time. Unaltered queens ≥ approximately 4 pounds body weight can be treated to prevent estrus. Administration of MA to pregnant dogs causes masculinization of female fetuses. There is no equivalent data for pregnant cats. MA has been used in feral cat colonies, administered by mixing it into food, at a much lower dose per cat. This type of dosing comes with less ability to control how much each cat eats. Because of this, ACC&D has historically advised against the use of MA in cat colonies and has not yet re-evaluated this position.

Description of the pharmaceutical

MA is a synthetic progestin which may be used to prevent pregnancy and estrus ("heat") cycles in dogs and cats, as well as other mammalian species. It has also been prescribed to treat certain skin and behavior problems in dogs and cats of both sexes. MA has been studied and used for dogs and cats over several decades in numerous countries under different brand names and at varying recommended doses. The product was approved by the FDA in 1975 for use in female dogs (Ovaban™). It was not developed for use in cats. It is not commonly used in the U.S. where both high rates of surgical neutering and concerns about MA’s side effects are high. Research to date strongly suggests that when considering the use of MA to prevent or suppress estrus, dosage and treatment duration are important in order to minimize the likelihood of adverse side effects.

Availability of megestrol acetate

Currently, MA can be prescribed under extra-label use guidelines from the FDA which include a veterinarian-client-patient relationship as well as other criteria some of which have been amended for Covid-194. MA is available via veterinary compounding pharmacies. It is advisable for each veterinarian to check their state law on compounding. In some states, veterinarians are permitted to order a supply of “office stock” of non-controlled prescription compounded medications from select compounding pharmacies, which can greatly reduce its cost, and then use that supply for individual cats. An oral liquid suspension of MA can be flavored (chicken, fish, etc.) and provided in a variety of container volumes. Then individual doses can be drawn into oral syringes. Although MA is available in other forms, practical considerations suggest MA compounded as a liquid suspension will be easier and more cost-effective to administer.

503B compounder Stokes Healthcare (800-754-5222) serving the U.S. nationwide can ship "office stock" directly to veterinarians if permitted by their state. This product is quite inexpensive. For example, a 30 mL vial of MA (10 mg/mL) contains 120 doses. The price quoted on April 2nd was $42 or 35 cents per dose (not including oral syringes or a $9.50 shipping fee for 2-day delivery). Popular compounding pharmacies Wedgewood and Roadrunner quoted similar prices. Stokes quoted a 6-month shelf life on the product. Veterinarians should check with their preferred compounding pharmacies for details pertaining to their situation and location.

Dosage suggestions

In a 2015 review of decades of research5, the recommended oral dosage for cats not showing estrus ("heat") signs is 2.5 mg/cat weekly (approximately 0.625 mg/kg/week) for up to 30 weeks. The oral dosage for cats showing signs of heat is higher at 5 mg/cat daily for three days followed by a 2.5 mg/cat dose weekly after that.


The literature suggests that in cats, the contraceptive effect takes place quickly but there is no available data to support this. It must be assumed that once a queen is off the medication, she will come into heat.


Potential adverse side effects in cats are more likely to occur at higher doses (>2.5 mg/cat). These side effects include diabetes mellitus, pyometra, adrenal gland suppression (Addison’s disease), mammary hyperplasia, and mammary cancer. Cats treated with MA sometimes develop diabetes mellitus, with or without related complications, that may or may not resolve after halting MA treatment. Diabetes mellitus has occurred at rates as high as 5-10% when cats are treated at higher doses (>2.5 mg/cat). Some side effects may resolve once the cat is taken off the medication.

Making this recommendation

The Alliance for Contraception in Cats and Dogs ( is a non-profit organization formed in 2000. Our mission is to advance non-surgical sterilants and contraceptives for cats and dogs and to promote their global accessibility. We envision a world in which dog and cat populations are effectively and humanely managed, improving the lives of dogs and cats and the people who care about them. It is up to each veterinarian to weigh the benefit of the need to prevent pregnancy to the health risks to the individual cat.

Advising this announcement

The decision to advise the field on the applicability of this interim contraceptive, not well-known in the U.S., was made in consultation with key ACC&D Board members and Scientific Advisors whose bios are on our website, specifically Cheri Asa, PhD; Julie Levy, DVM, PhD, DACVIM; Linda Rhodes, VMD, PhD; and Michelle Kutzler, MBA, DVM, PhD, DACT. 

The American College of Theriogenologists is in agreement that there may be viable non-surgical short-term options to prevent pregnancy in certain cats during this current Covid-19 pandemic, and encourages owners to consult with their primary care veterinarian or a theriogenologist to discuss potential treatment.

We will continue to update this resource as more input is received.

Additional Information

For additional information, including links to journal articles, visit our MA Additional Resources page.


  1. National Animal Care & Control Association statement encouraging the release of unaltered pets from animal shelters. 
  2. Shelter Medicine programs' statement and recommendations for transport and animal movement during COVID-19 pandemic - updated 3/28/20. 
  3. Open Letter from Dr. Julie Levy, “Why we must suspend S/N surgeries NOW.”
  4. U.S. Food and Drug Administration, The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians. Note: on 3/24/20 the FDA issued a press release stating,

    “In order to help veterinarians utilize telemedicine to address animal health needs during the COVID-19 pandemic, the FDA generally does not intend to enforce the animal examination and premises visit portion of the VCPR requirements relevant to the FDA regulations governing Extralabel Drug Use in Animals… This will allow veterinarians to prescribe drugs in an extralabel manner or authorize the use of VFD drugs without direct examination of or making visits to their patients, which will limit human-to-human interaction and potential spread of COVID-19 in the community.”

    The full policy document (CVM GFI #269) can be found here

  5. Romagnoli, S. “Progestins to control feline reproduction: Historical abuse of high doses and potentially safe use of low doses” Journal of Feline Medicine and Surgery (2015) 17:743–751.

This page will be updated as new information becomes available. Check back for the most current info and follow us on Facebook to be notified about updates.

List of Important Updates

July 9, 2020

  • Survey on megestrol acetate now open. Please take the survey before it closes on July 26th. More info here.

June 10, 2020

  • Survey Worksheet added to MA Additional Resources page. Worksheet is designed to provide an idea of what information will be requested in our upcoming survey on MA use, and it can be used as a reference aid when completing the survey to save time.

June 1, 2020

  • Side Effects List and Tips and Tracking Sheet (for monitoring MA doses and side effects) added to More Resources section of  MA Additional Resources page.

May 11, 2020

  • This info now available in Spanish.

April 27, 2020

April 20, 2020

  • ASPCA's statement of support for veterinarians considering MA as a temporary contraceptive added to MA Additional Resources.
  • Supporting statements from Dr. Julie Levy and Dr. Michael Greenberg added to materials. 

April 14, 2020

April 11, 2020

April 9, 2020

April 7, 2020

April 7, 2020

April 6, 2020

  • FDA's change to its enforcement policy regarding federal VCPR requirements added to "Availability" section. See also citation 4.

April 3, 2020

  • Statement from The American College of Theriogenologists added to "Advising this announcement" section.
  • Link to The Society for Theriogenology's member search page added to "Important references for practitioners" section.

April 2, 2020